Literature DB >> 10047432

T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides.

R Abulafia-Lapid1, D Elias, I Raz, Y Keren-Zur, H Atlan, I R Cohen.   

Abstract

T cell responses to peptide epitopes of the 60 kDa heat shock protein (hsp60) have been shown to play a role in the pathogenesis of type 1 insulin-dependent diabetes mellitus (IDDM) in mice. To test whether hsp60 autoimmunity might be involved in human type 1 diabetes, we studied T cell proliferative responses (stimulation index; SI) to intact human hsp60, to hsp60 peptides and to a recall antigen (tetanus toxoid) in 25 newly diagnosed type 1 diabetes patients, in 22 type 2 (non-insulin-dependent diabetes mellitus, NIDDM) patients, and in 25 healthy blood donors. There were no significant differences between the T cell responses of the three groups to tetanus toxoid. However, the responses to hsp60 of the type 1 diabetes group (median SI=5) were significantly greater (P<0. 01) than those of the type 2 group (median SI=1.67) and of the blood donors (median SI=1.7). Epitope mapping revealed significant responses to at least seven different peptides, with prevalent responses to the p277 peptide previously mapped in NOD mice and to peptide p32. Thus, newly diagnosed type 1 diabetes patients, similar to prediabetic and newly diabetic NOD mice, show heightened autoimmunity to hsp60 and hsp60 peptides. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10047432     DOI: 10.1006/jaut.1998.0262

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  35 in total

1.  The stress kit: a new method based on competitive reverse transcriptase-polymerase chain reaction to quantify the expression of human alphaB-crystallin, Hsp27, and Hsp60.

Authors:  J J Bajramović; S B Geutskens; M Bsibsi; M Boot; R Hassankhan; K C Verhulst; J M van Noort
Journal:  Cell Stress Chaperones       Date:  2000-01       Impact factor: 3.667

2.  Mapping of the immunodominant T cell epitopes of the protein topoisomerase I.

Authors:  S Veeraraghavan; E A Renzoni; H Jeal; M Jones; J Hammer; A U Wells; C M Black; K I Welsh; R M du Bois
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

Review 3.  Heat shock protein 70: roles in multiple sclerosis.

Authors:  María José Mansilla; Xavier Montalban; Carmen Espejo
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

4.  Type 1 diabetes associated HLA-DQ2 and DQ8 molecules are relatively resistant to HLA-DM mediated release of invariant chain-derived CLIP peptides.

Authors:  Zemin Zhou; Eduardo Reyes-Vargas; Hernando Escobar; Brant Rudd; Alan L Rockwood; Julio C Delgado; Xiao He; Peter E Jensen
Journal:  Eur J Immunol       Date:  2016-01-22       Impact factor: 5.532

Review 5.  T-cell autoantigens in the non-obese diabetic mouse model of autoimmune diabetes.

Authors:  Jeffrey Babad; Ari Geliebter; Teresa P DiLorenzo
Journal:  Immunology       Date:  2010-10-13       Impact factor: 7.397

Review 6.  The role of immune tolerance in preventing and treating arthritis.

Authors:  Gijs Teklenburg; Salvatore Albani
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

7.  An update on the use of NOD mice to study autoimmune (Type 1) diabetes.

Authors:  Rodolfo José Chaparro; Teresa P Dilorenzo
Journal:  Expert Rev Clin Immunol       Date:  2010-11       Impact factor: 4.473

Review 8.  Clinical potential of antigen-specific therapies in type 1 diabetes.

Authors:  Ken T Coppieters; Birgit Sehested Hansen; Matthias G von Herrath
Journal:  Rev Diabet Stud       Date:  2012-12-28

9.  Heat-shock proteins: inflammatory versus regulatory attributes.

Authors:  Verônica Coelho; Femke Broere; Robert J Binder; Yehuda Shoenfeld; Kamal D Moudgil
Journal:  Cell Stress Chaperones       Date:  2008-02-28       Impact factor: 3.667

Review 10.  Trials in type 1 diabetes: Antigen-specific therapies.

Authors:  Ken T Coppieters; Leonard C Harrison; Matthias G von Herrath
Journal:  Clin Immunol       Date:  2013-02-15       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.